Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Teserpaturev - Daiichi Sankyo Company/University of Tokyo

Next Previous
Drug Profile

Teserpaturev - Daiichi Sankyo Company/University of Tokyo

Alternative Names: DELYTACT; DS 1647; G47 delta oncolytic virus therapy - Daiichi Sankyo/University of Tokyo; G47Δ oncolytic virus therapy - Daiichi Sankyo/University of Tokyo; Oncolytic herpes simplex virus type I - Daiichi Sankyo Company/University of Tokyo

Latest Information Update: 23 Jul 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Tokyo
  • Developer Daiichi Sankyo Company; University of Tokyo
  • Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity No

Highest Development Phases

  • Marketed Glioma
  • Phase II Prostate cancer
  • Phase I Neuroblastoma
  • Discontinued Malignant-mesothelioma

Most Recent Events

  • 23 Jul 2026 Discontinued - Phase-I for Malignant mesothelioma (Inoperable/Unresectable, Second-line therapy or greater) in Japan (Intrapleural) (Daiichi Sankyo Company Website, July 2026)
  • 27 Apr 2026 Teserpaturev is still in phase-II trials for prostate cancer in Japan (jRCTs033210603)
  • 21 Jul 2022 Daiichi Sankyo terminates phase II trial in Glioblastoma in Japan due to sponsor's decision (UMIN000015995)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top